Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of sandbufalin in prevention/treatment of asthma drugs

A technology of sandbuad toxin and asthma, which is applied in the field of medicine to achieve significant therapeutic effects, improve goblet cell hyperplasia, and improve lung tissue inflammatory infiltration

Active Publication Date: 2020-07-14
YUNNAN UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The present invention relates to the action and efficacy of sabubufondin in anti-asthma, and no related reports have been seen yet

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of sandbufalin in prevention/treatment of asthma drugs
  • Application of sandbufalin in prevention/treatment of asthma drugs
  • Application of sandbufalin in prevention/treatment of asthma drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Example 1 Observation of the drug effect of sabuad toxin on OVA-induced mouse asthma model

[0038] 1. Test method

[0039] 1.1 Grouping and Modeling

[0040] 40 healthy BALB / c female mice were randomly divided into 4 groups, 10 mice in each group, which were control group, model group, dexamethasone group, and sabuadin drug group.

[0041] In the dexamethasone group and the sabuad toxin drug group, mice were intraperitoneally injected with 1 mg of aluminum hydroxide (emulsified with 20 μg of OVA) on the first day of the experiment, and treated in the same way on the seventh and fifteenth day. After 21-23 days, the airway of mice was treated with OVA (50 mg / mL normal saline) for 30 min for 7 consecutive days, once a day. The dexamethasone group (1 mg / kg) and the sabuad toxin drug group (2 mg / kg) were intragastrically administered after OVA sensitization. In the control group, the mice were intraperitoneally injected with normal saline instead of OVA solution on the 1...

Embodiment 2

[0076] Example 2 The mechanism of action of sabubufoni to improve asthma in mice

[0077] 1. Test method

[0078] 1.1 Grouping and Modeling

[0079] 40 healthy BALB / c female mice were randomly divided into 4 groups, 10 mice in each group, which were control group, model group, dexamethasone group, and sabuadin drug group.

[0080] In the dexamethasone group and the sabuad toxin drug group, mice were intraperitoneally injected with 1 mg of aluminum hydroxide (emulsified with 20 μg of OVA) on the first day of the experiment, and treated in the same way on the seventh and fifteenth day. After 21-23 days, the airways of the mice were treated with OVA (50 mg / ml normal saline) for 30 min for 7 consecutive days, once a day. The dexamethasone group (1 mg / kg) and the sabuad toxin drug group (2 mg / kg) were intragastrically administered after OVA sensitization. In the control group, the mice were intraperitoneally injected with normal saline instead of OVA solution on the 1st, 7th, an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of arenobufagin in preparing a drug for preventing / treating an asthmic disease. Experiments prove that the arenobufagin can lower inflammatory cell infiltration andairway mucus hypersecretion in asthma model mouse lung tissues. The arenobufagin can exert the effect of treating asthma by inhibiting expressions of Eotaxin, IL-13 and IL-8 in a bronchoalveolar lavage fluid. The arenobufagin has an application prospect of treating the asthmic disease.

Description

technical field [0001] The invention belongs to the technical field of medicines, and in particular relates to the application of sabubufafen in medicines for preventing / treating asthma. Background technique [0002] Bronchial asthma, referred to as asthma (Asthma), is a recurrent chronic airway inflammatory disease characterized by airway hyperresponsiveness, airway inflammation and airway remodeling, involving a variety of inflammatory cells. The World Health Organization (WHO) reported that "the harm and economic burden caused by asthma to human health exceeds the sum of tuberculosis and AIDS". With the aggravation of environmental pollution, the morbidity and mortality of asthma are increasing year by year. At present, there are about 300 million asthmatic patients in the world, among them, there are about 30 million asthmatic patients in my country, and it shows a clear upward trend year by year. Therefore, the development of asthma drugs has important social signific...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/585A61P11/06
CPCA61K31/585A61P11/06
Inventor 李宝晶黄丰何红平王亭孙赟杨竹雅
Owner YUNNAN UNIV OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com